Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis | Zendy

WonJung Koh | Zendy; OhJung Kwon | Zendy; HoShin Gwak | Zendy; Jong Woo Chung | Zendy; S.-N. Cho | Zendy; W. S. Kim | Zendy; Tae Sun Shim | Zendy

Open Access

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

Author(s) -

WonJung Koh,

OhJung Kwon,

HoShin Gwak,

Jong Woo Chung,

S.-N. Cho,

W. S. Kim,

Tae Sun Shim

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp171

Subject(s) - linezolid , medicine , interquartile range , regimen , extensively drug resistant tuberculosis , culture conversion , tuberculosis , surgery , sputum , mycobacterium tuberculosis , vancomycin , staphylococcus aureus , pathology , biology , bacteria , genetics

Although previous studies have suggested that linezolid may be effective for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), the optimal dose of linezolid for intractable MDR/XDR-TB is not clear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research